...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of drugs in dermatology: JDD >IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A
【24h】

IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A

机译：IncObotulinumtoxina：高度纯化和精确制造的肉毒杆菌神经毒素类型A型

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aesthetic dermatologic applications of botulinum neurotoxin (BoNT), including treatment of glabellar lines, horizontal forehead lines, and crow's feet, were the most common non-surgical cosmetic procedures in the US in 2017, with high levels of subject satisfaction. Since the first BoNT type A (BoNT-A) formulation was approved in 1989, the number of formulations available on the world's commercial markets has increased and new approvals are expected. BoNT is produced by Clostridium botulinum in nature as part of a large protein complex. However, the unnecessary clostridia! proteins, which dissociate from BoNT under physiological conditions with a half-life of 1 minute, have no role in clinical applications. Data demonstrate that BoNT administration can elicit an immunological response, leading to production of neutralizing antibodies that can be associated with reduced efficacy or treatment non-response. As repeat treatments are required to maintain efficacy, clinicians should be aware of the possibility of antibody development and choose a BoNT with the lowest risk of immunogenicity. IncobotulinumtoxinA is manufactured using advanced technology to precisely isolate the pure BoNT without unnecessary clostridial proteins, and with low immunogenicity and high specific activity. In incobotulinumtoxinA clinical studies, no previously BoNT-naive subjects developed neutralizing antibodies, and there was no secondary non-response to incobotulinumtoxinA treatment. Here we review the role of unnecessary clostridial proteins in BoNT-A and discuss the unique incobotulinumtoxinA manufacturing and purification process with a focus on the implications for use in aesthetic medicine.
机译：肉毒杆菌神经毒素（BONT）的审美皮肤病应用，包括腹股沟线，水平前额线和乌鸦脚的治疗，是2017年美国最常见的非手术化妆品，具有高水平的主题满足感。由于1989年首次批准了（Bont-A）制定，因此世界商业市场上可用的配方数量增加，预计会有新的批准。 Bont是由梭菌肉毒杆菌生成的，作为大蛋白质复合物的一部分。但是，不必要的锦缎！蛋白质，其在生理条件下与临床应用的半衰期离子异常，在临床应用中没有作用。数据表明，扰乱给药可以引起免疫学反应，导致能够产生与降低的疗效或治疗不反应相关的中和抗体。随着重复治疗需要保持疗效，临床医生应该意识到抗体发育的可能性，并选择具有最低免疫原性风险的骚动。使用先进技术制造Incobotulinumtoxina，以精确地分离纯的闭合蛋白，并且具有低免疫原性和高比活性。在Incobotulinumtoxina临床研究中，未以前没有突然的受试者发育中和抗体，并且没有对IncobotiNumtoxina治疗的二次非反应。在这里，我们审查了不必要的梭菌蛋白在Obon-A中的作用，并讨论了独特的IncobotiNumtoxina制造和纯化过程，重点是在美学医学中使用的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号